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Abstract
Rationale: Primitive small cell carcinoma of the ureter is extremely rare, in this case report is meticulously described its aggressive
clinical course and the pathological clues that help with the diagnosis. Also, a detailed table with the clinico-pathological features of
analogous case reports in literature is provided.
Patient concerns: A 79-year-old female presented with gross hematuria and ﬂank pain.
Diagnoses: Small cell carcinoma of the ureter. The surgical specimen showed a mixed histology of small cell carcinoma and
transitional cell carcinoma; the common neuroendocrine markers (chromogranin A, synaptophysin, CD56) were positive, and
vimentin and thyroid transcription factor 1 were negative. The patient had an advanced stage at presentation with regional nodes
involvement (pT3N1).
Interventions:Segmental ureterectomy was performed but it was only possible to administer 1 cycle of platinum-based adjuvant
chemotherapy due to the rapid decline of her clinical parameters.
Outcomes: The disease rapidly spread locally and metastasized.
Lesson: The clinicians must be aware of this aggressive tumor with silent clinical course and advanced stages at presentation.
Abbreviations: CT = computed tomography, CK = cytokeratin, SCC = small cell carcinoma, TTF-1 = thyroid transcription
factor 1.
Keywords: carcinoma, case report, mixed histotype, neuroendocrine, pathology, small cell, urology1. Introduction
Primary small cell carcinoma (SCC) of the urinary tract is a rare
cancer, accounting for less than 0.5% of urinary tract tumors,[1]
mostly localized in thebladder andprostate,while its localization in
the renal pelvis or in the ureter is extremely rare. Smoking exposure
causes reactive and genetic damage to the tissues, and is amain risk
factor for urothelial carcinoma and small cell neuroendocrine
carcinoma.[2] Being such a rare disease, the pathogenesis is still
unclear, and 2 theories have been postulated. The ﬁrst claims its
origin from a neuroendocrine cell population derived from the
neural crest (enterochromafﬁn cells) migrated in the genitourinary
tract during embryogenesis; the second theorizes its genesis fromEditor: N/A.
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1the pluripotent epithelial cells of the genitourinary tract. The latter
could explain the common ﬁnding of a mixed histologic proﬁle
(transitional cell carcinoma, squamous cell carcinoma, adenocar-
cinoma, sarcomatoid carcinoma, and sarcoma), often described as
a gradual transition from 1 subtype to the other.
Small cell carcinoma of the ureter has been described in about
40 patients so far[3–35] with similarities in symptoms, manage-
ment, and outcome, as outlined in Table 1.2. Case report
A 79-year-old female presented with right-sided back pain and
gross hematuria. Her clinical history was signiﬁcant for atrial
ﬁbrillation treated with oral anticoagulant, which was suspended
due to hematuria. She had a smoking history of more than 20
cigarettes per day for nearly 60 years. Physical examination
revealed pain at the right costovertebral angle extended to the
right groin over the location of the ureter. Creatinine levels at the
admission were 1.37mg/dL. Abdominal ultrasound was immedi-
ately performed, revealing a grade 3 right hydronephrosis
without lithiasis and hematic material in the bladder. A
functional scintigraphy study with 99mTc-diethylene-triamine-
penta-acetate revealed a decreased function of the right kidney,
and the calculated glomerular ﬁltration rate (GFR, Gatesmethod)
was 27mL/min for the right kidney and 40mL/min for the left
kidney. At cystoscopic examination, the bladder wall was
irregular in the right emitrigon, and the right ureteral oriﬁce
was swollen and bleeding. Urine cytology showed atypical
morphological features, classiﬁed as suspicious for high-grade
urothelial carcinoma (the Paris System for reporting urinary
cytology). The following abdominal computed tomography
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Figure 1. (A) Panoramic view of the ureteral tumor, hematoxylin–eosin stain (H&E). (B) The transitional cell carcinoma (red triangle) inﬁltrates the ureteral wall
together with the small cell carcinoma (SCC) component with a clear lymphovascular invasion (black triangle) (H&E 10x). (C) The transitional cell carcinoma is
intermixed with the SCC (H&E 20x). (D–F) The neuroendocrine markers are all positive in the SCC component (D: CD56, 10x; E: synaptophysin, 10x; F:
chromogranin-A, 2x). (G) Ki-67 is remarkably high, especially in the SCC component of the tumor (2x). (H) TTF-1 immunohistochemistry is completely negative (2x).
(I) The transitional cell carcinoma is CK7 positive (2x).
Farci et al. Medicine (2018) 97:24 Medicine(CT) scan found thickened walls in the distal part of the right
ureter in the absence of lithiasis. A nephroureterectomy was
planned, but had to be suspended due to the patient’s clinical
condition, and a segmental ureterectomy was performed instead.
The right distal ureter was resected together with some enlarged
regional nodes; its macroscopic inspection showed a thickened
and hemorrhagic wall, with a nodular neoplasm of 21.5cm
obstructing the lumen and inﬁltrating the surrounding adipose
tissue. The tumor was composed of small cell carcinoma admixed
with inﬁltrating transitional cell carcinoma (Fig. 1). The
neuroendocrine markers (synaptophysin, chromogranin-A,
CD56) were positive in the SCC part of the tumor, the mitotic
count was high, and the proliferative index counted by Ki-67 was
more than 90%; the tumor was negative for vimentin and TTF-1.
The ﬁnal diagnosis was small cell neuroendocrine carcinoma
invading 80% of the surgical specimen associated with high-
grade urothelial carcinoma, both inﬁltrating the ureteral wall, the
perineural spaces, and the perivisceral adipose tissue. The
ureteral resection margins were negative. The right external iliac
and presacral nodes were both metastatic for small cell
neuroendocrine carcinoma. The pathological stage at the
diagnosis was pT3N1 and the patient underwent a 2-week cycle
of etoposide chemotherapy that had to be suspended for renal
failure. The disease rapidly progressed: at 2 and a half months
after admission and less than a month after segmental ureter-4ectomy, an abdominal CT scan showed a contrast-enhanced
1910cm mass surrounding and obstructing the ureter,
extended without clear margins to the aortocaval space,
displacing the iliac vessels and inﬁltrating the surrounding
tissues with diffuse pelvic lymphadenopathy. Chest and cranial
CT scan did not detect any other lesions. The patient died for the
progression of disease 5 months after admission.
3. Discussion
The usual presentation is ﬂank homolateral pain due to
hydronephrosis (with or without irradiation to the groin) and
gross hematuria due to the vascular invasion; less frequently the
patient laments weight loss, dysuria, and urinary tract infection.
When those symptoms appear, the disease might be already at
late stages, also because the pain gradually increases over time,
becoming chronic, allowing a differential diagnosis from lithiasis
that presents as acute pain. Ultrasonography is the initial choice
for imaging in a suspected obstruction of the urinary tract,
helping the clinician to differentiate between lithiasis and other
causes of obstruction; urography and CT scan are second-level
procedures that allow to establish the presence of a mass, conﬁrm
an associated hydronephrosis due to the obstruction, and the
extension of the tumor and the regional node status. Urine
cytology can be a precious diagnostic tool, but it requires an
Farci et al. Medicine (2018) 97:24 www.md-journal.comexpert cytologist to get the right diagnosis, considering the
paucity of the neoplastic cells in the smear, the mixed histotypes,
and the infrequency of small cell carcinoma. A CT-guided biopsy
or a nephro-ureteral resection are the usual choices for the
urologist, allowing a pathological diagnosis.
At gross examination, SCC is usually described as a ﬁrm
greyish tumor, often with hemorrhagic areas, protruding and
occluding the ureteral lumen, with ill-deﬁned borders and with
peritumoral wall thickening. Small cell carcinoma has an
architecture similar to the neuroendocrine tumors of other sites,
composed by solid sheets or different pattern such as rosette or
nests, often associated with a desmoplastic reaction. Crush
artefact (“Azzopardi effect”) is common. The cells are small to
medium-sized with scant cytoplasm and prominent nucleus with
granular (classically described as “salt and pepper”) chromatin.
Mitosis and necrosis are frequent, and also vascular invasion. As
previously mentioned, there may coexist other histological types
such as squamous carcinoma, transitional carcinoma, adenocar-
cinoma, and sarcomatoid carcinoma. The differential diagnoses
include poorly differentiated urothelial carcinoma, primitive
neuroectodermal tumor, malignant lymphoma, lymphoepithe-
lioma-like carcinoma, and plasmacytoid carcinoma, from which
this tumor can be differentiated by immunohistochemistry.[27]
The neuroendocrine stains are usually positive (chromogranin A,
synaptophysin, CD56, neuron-speciﬁc enolase) and it may show
positivity for keratins such as cytokeratin (CK)7, epithelial
membrane antigen, and pan-CK. Uroplakin III is usually
negative, and this may help the differential diagnosis with
transitional cell carcinoma. Vimentin expression has been
previously related to a higher metastatic potential and a poor
outcome in a clinical report.[30] The tumor is frequently
diagnosed at late stages, when it has already invaded the peri-
uretheral tissues and the surrounding structures. The overall
median survival is 17 months, with a 51.9% of 1-year survival
rate.[3] The primary treatment is surgical remotion of the tumor
by ureterectomy or nephroureterectomy depending on the clinical
status of the patient, stage, and localization of the tumor. Due to
the aggressive course of SCC, the surgeon must address the
radicality of the excision as early as possible, considering that in
most cases the resection alone does not seem to stop the
progression of the disease. If the clinical parameters of the patient
are stable, the surgical treatment is usually followed by adjuvant
chemotherapy and radiotherapy. It is important to note that the
patient might be anemic for the long-term hematuria, and the
obstruction caused by the tumor often causes hydronephrosis and
impaired kidney function, so the clinical status of the patient
might hinder a radical excision and/or an effective course of a
systemic chemotherapy. There are promising reports about
neoadjuvant chemotherapy, which has been used successfully to
downstage the disease and lengthen the overall survival.[10,11,36]4. Conclusions
Small cell carcinoma of the ureter is an aggressive disease, and the
factors that seem correlate with its prognosis are smoking history,
age, male sex, tumor size, nodes, metastasis grading and size at
diagnosis, the expression of vimentin, and incomplete resection.
Although this is a rare tumor, effective targeted therapies are
expected to be applied to improve the overall survival.Author contributions
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